Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antigens, Neoplasm | 10 | 2019 | 230 | 1.74 | Why? |
| Immunotherapy | 7 | 2021 | 2421 | 0.79 | Why? |
| Interleukin-1beta | 3 | 2021 | 992 | 0.63 | Why? |
| Biomarkers, Tumor | 4 | 2017 | 1314 | 0.62 | Why? |
| Cancer Vaccines | 5 | 2019 | 136 | 0.56 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.55 | Why? |
| Membrane Proteins | 7 | 2019 | 1733 | 0.52 | Why? |
| Nanomedicine | 1 | 2017 | 329 | 0.50 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2021 | 2483 | 0.45 | Why? |
| Neoplasms | 8 | 2019 | 17251 | 0.34 | Why? |
| Interleukin-6 | 3 | 2021 | 7522 | 0.30 | Why? |
| Langerhans Cells | 1 | 2004 | 14 | 0.29 | Why? |
| Nanoparticles | 1 | 2017 | 2040 | 0.29 | Why? |
| Tumor Microenvironment | 4 | 2019 | 264 | 0.26 | Why? |
| Dendritic Cells | 4 | 2019 | 1330 | 0.26 | Why? |
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 1014 | 0.24 | Why? |
| Ipilimumab | 2 | 2018 | 102 | 0.22 | Why? |
| Lentivirus | 2 | 2019 | 310 | 0.21 | Why? |
| Lipid A | 1 | 2019 | 32 | 0.20 | Why? |
| Cell Separation | 1 | 2021 | 270 | 0.19 | Why? |
| CD8-Positive T-Lymphocytes | 4 | 2021 | 5837 | 0.18 | Why? |
| Sarcoma, Synovial | 1 | 2017 | 8 | 0.18 | Why? |
| Melanoma-Specific Antigens | 1 | 2017 | 2 | 0.18 | Why? |
| Immunity, Mucosal | 1 | 2021 | 426 | 0.17 | Why? |
| CTLA-4 Antigen | 1 | 2018 | 282 | 0.17 | Why? |
| Antigen-Presenting Cells | 1 | 2017 | 206 | 0.16 | Why? |
| Lung Neoplasms | 3 | 2018 | 3228 | 0.16 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.15 | Why? |
| Sarcoma | 1 | 2019 | 290 | 0.15 | Why? |
| Interferon-gamma | 2 | 2012 | 2711 | 0.15 | Why? |
| Carcinoma, Transitional Cell | 1 | 2017 | 198 | 0.15 | Why? |
| Genetic Vectors | 2 | 2019 | 1600 | 0.14 | Why? |
| Glucosides | 1 | 2019 | 359 | 0.14 | Why? |
| Leukocytes | 1 | 2021 | 1046 | 0.13 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 316 | 0.13 | Why? |
| Urologic Neoplasms | 1 | 2017 | 348 | 0.13 | Why? |
| Intestinal Mucosa | 1 | 2021 | 1046 | 0.12 | Why? |
| Immunotherapy, Adoptive | 1 | 2017 | 524 | 0.12 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.12 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.12 | Why? |
| Ovarian Neoplasms | 1 | 2017 | 465 | 0.11 | Why? |
| Bacterial Vaccines | 1 | 2012 | 139 | 0.11 | Why? |
| Workflow | 1 | 2021 | 2373 | 0.11 | Why? |
| Multiple Myeloma | 1 | 2020 | 1064 | 0.11 | Why? |
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 6653 | 0.10 | Why? |
| Adenocarcinoma | 1 | 2017 | 651 | 0.10 | Why? |
| Adjuvants, Immunologic | 1 | 2019 | 1709 | 0.10 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.09 | Why? |
| Carcinoma, Squamous Cell | 1 | 2017 | 902 | 0.09 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.08 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.08 | Why? |
| Mutation | 2 | 2017 | 12376 | 0.08 | Why? |
| New York City | 4 | 2021 | 7432 | 0.08 | Why? |
| Single-Cell Analysis | 1 | 2017 | 2450 | 0.08 | Why? |
| Biological Products | 1 | 2021 | 2331 | 0.08 | Why? |
| Gastrointestinal Diseases | 1 | 2021 | 2580 | 0.07 | Why? |
| Killer Cells, Natural | 3 | 2021 | 2093 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Drug Resistance, Neoplasm | 2 | 2018 | 447 | 0.07 | Why? |
| Head and Neck Neoplasms | 1 | 2017 | 1568 | 0.07 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.07 | Why? |
| HLA-A2 Antigen | 1 | 2004 | 134 | 0.07 | Why? |
| Cell Line, Tumor | 2 | 2018 | 3608 | 0.07 | Why? |
| Inflammatory Bowel Diseases | 1 | 2021 | 3209 | 0.06 | Why? |
| Disease-Free Survival | 2 | 2019 | 1654 | 0.06 | Why? |
| Transforming Growth Factor beta1 | 1 | 2004 | 204 | 0.06 | Why? |
| HLA-A Antigens | 1 | 2004 | 196 | 0.06 | Why? |
| Liver | 1 | 2017 | 4007 | 0.06 | Why? |
| Humans | 27 | 2021 | 930598 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Transforming Growth Factor beta | 1 | 2004 | 363 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.06 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.06 | Why? |
| CD57 Antigens | 1 | 2021 | 96 | 0.06 | Why? |
| Female | 17 | 2021 | 380317 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Aged | 12 | 2021 | 215776 | 0.06 | Why? |
| Recombinant Proteins | 2 | 2019 | 3786 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.06 | Why? |
| Antigen Presentation | 1 | 2004 | 524 | 0.05 | Why? |
| CD56 Antigen | 1 | 2021 | 193 | 0.05 | Why? |
| Male | 15 | 2021 | 367725 | 0.05 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.05 | Why? |
| Chemokine CCL3 | 1 | 2020 | 103 | 0.05 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.05 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.05 | Why? |
| Phenotype | 2 | 2017 | 4037 | 0.05 | Why? |
| Inflammation Mediators | 2 | 2021 | 2654 | 0.05 | Why? |
| Immunohistochemistry | 2 | 2017 | 2275 | 0.05 | Why? |
| Molecular Sequence Data | 1 | 2004 | 3198 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Interleukin-18 | 1 | 2020 | 328 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.04 | Why? |
| Cell Differentiation | 1 | 2004 | 1338 | 0.04 | Why? |
| Molecular Targeted Therapy | 2 | 2017 | 1579 | 0.04 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.04 | Why? |
| Neoplasm Staging | 2 | 2017 | 1999 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Agammaglobulinemia | 1 | 2020 | 213 | 0.04 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.04 | Why? |
| Genetic Heterogeneity | 1 | 2017 | 77 | 0.04 | Why? |
| Deoxycytidine | 1 | 2017 | 116 | 0.04 | Why? |
| National Cancer Institute (U.S.) | 1 | 2017 | 155 | 0.04 | Why? |
| Cisplatin | 1 | 2017 | 209 | 0.04 | Why? |
| Injections, Intramuscular | 1 | 2019 | 800 | 0.04 | Why? |
| Host-Pathogen Interactions | 3 | 2021 | 11041 | 0.04 | Why? |
| Drugs, Investigational | 1 | 2019 | 198 | 0.04 | Why? |
| Nitriles | 1 | 2021 | 1053 | 0.04 | Why? |
| Toll-Like Receptor 4 | 1 | 2019 | 390 | 0.04 | Why? |
| Neoplasm Grading | 1 | 2017 | 400 | 0.04 | Why? |
| Interleukin-17 | 1 | 2020 | 602 | 0.04 | Why? |
| DNA Damage | 1 | 2017 | 285 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Maryland | 1 | 2017 | 436 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2017 | 582 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2017 | 581 | 0.04 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.04 | Why? |
| HIV Infections | 1 | 2020 | 11620 | 0.04 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.04 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.04 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.03 | Why? |
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 291 | 0.03 | Why? |
| Lymphatic Metastasis | 1 | 2017 | 537 | 0.03 | Why? |
| Neoplasm Metastasis | 1 | 2017 | 682 | 0.03 | Why? |
| Pneumonectomy | 1 | 2017 | 278 | 0.03 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.03 | Why? |
| HIV | 1 | 2020 | 1116 | 0.03 | Why? |
| Radiotherapy | 1 | 2018 | 608 | 0.03 | Why? |
| Pyrimidines | 1 | 2021 | 1557 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Serratia marcescens | 1 | 2012 | 38 | 0.03 | Why? |
| Lymphocytes | 1 | 2006 | 3056 | 0.03 | Why? |
| Amino Acid Sequence | 1 | 2004 | 6049 | 0.03 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 1165 | 0.03 | Why? |
| Clinical Trials as Topic | 2 | 2017 | 7330 | 0.03 | Why? |
| New York | 1 | 2020 | 2488 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2021 | 1783 | 0.03 | Why? |
| Streptococcus pyogenes | 1 | 2012 | 118 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.03 | Why? |
| Cell Proliferation | 1 | 2019 | 1973 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.03 | Why? |
| Animals | 2 | 2019 | 78931 | 0.03 | Why? |
| Adult | 8 | 2021 | 244371 | 0.03 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Pyrazoles | 1 | 2021 | 1791 | 0.03 | Why? |
| Cells, Cultured | 1 | 2021 | 5835 | 0.02 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.02 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.02 | Why? |
| Autopsy | 1 | 2021 | 3495 | 0.02 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 1645 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Autoantibodies | 1 | 2020 | 2094 | 0.02 | Why? |
| Cell Line | 1 | 2004 | 12040 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Infant | 2 | 2021 | 30274 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Signal Transduction | 1 | 2004 | 7207 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.02 | Why? |
| Cause of Death | 1 | 2021 | 4823 | 0.02 | Why? |
| Body Temperature | 1 | 2012 | 875 | 0.02 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2019 | 3231 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4545 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2019 | 4624 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Hypoxia | 1 | 2017 | 3626 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
Gnjatic's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(197)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(265)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_